CYP19A1 and cancer: Furthermore, tamoxifen or aromatase inhibitors could be considered more for those at higher risk of contralateral second primary cancers, as studies have shown that the benefits of 5 years of tamoxifen in the prevention setting persist for at least 11 years after treatment cessation (42).